Two key contrasts stood out in the European Parliament debate concerning the proposed Critical Medicines Act: rapporteur Tomislav Sokol (EPP) championed bolstering EU-based pharmaceutical production and increased EU coordination, while Christine Anderson (ESN) and other members warned against expanding EU powers, citing risks of centralisation and excessive regulatory burdens. This divide foregrounds a classic EU tension between strengthening integration through coordinated policies and safeguarding national sovereignty, particularly in health security.
Held on January 19, 2026, the plenary session addressed the EU Commission’s draft legislation aimed at enhancing the availability and security of critical medicinal products within the EU. This initiative seeks to tackle persistent medicine shortages and reduce external dependence, exposed in crises like COVID-19, by fostering EU manufacturing and supply chain diversification.
The most detailed policy proposals came from Tomislav Sokol (EPP), advocating for EU-based production as a prerequisite in public procurement contracts and promoting strategic autonomy. Supporting him were MEPs including Tilly Metz (Greens) and Jessica Polfjärd (EPP), who pushed for local manufacturing and reduced dependency on third countries. They envision a communal effort to establish joint procurement and stockpiling mechanisms with measurable goals for reducing reliance on imports.
In contrast, Christine Anderson (ESN) expressed skepticism regarding the Act’s expansion of regulatory oversight, particularly environmental requirements she saw as an undue burden on producers and a barrier for smaller pharmaceutical companies. Others like Marie-Luce Brasier-Clain (PfE) cautioned that EU centralisation measures, such as the redistribution of national stockpiles, infringe on member states’ sovereignty. These concerns highlight the tension between consumer protection and business competitiveness, with possible negative impacts on smaller EU producers who may face increased compliance costs.
Supporting the integrationist stance, Nicolae Ștefănuță (Greens/EFA) and Michalis Hadjipantela (EPP) emphasized that coordinated EU responses would foster solidarity across regions and ensure equitable access to medicines, especially benefiting smaller member states. However, opposition regarded such mechanisms as potentially disruptive to national healthcare systems.
The debate also touched on sensitive issues like the exclusion of abortion-related medicines from the critical list, with some members urging their inclusion to ensure access, while others avoided firm commitments, deferring to national constitutional prerogatives.
The main policy orientations thus diverged between a push for extending EU regulatory and procurement powers to guarantee medicine availability and a demand for preserving member states’ authority and minimizing burdens on businesses. Stakeholders impacted include EU producers, facing new environmental and procurement standards; national authorities, whose sovereignty on stockpile management is contested; EU consumers, who might gain from increased availability; and industry sectors wary of increased operational costs.
Looking ahead, the European Commission remains open to trilogue negotiations, aiming to finalize the Act swiftly to deliver on its access guarantees. The Parliament’s vote scheduled for the following day will test whether a pragmatic compromise bridging integration and subsidiarity can be achieved.